These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Glucose Metabolism as a Pre-clinical Biomarker for the Golden Retriever Model of Duchenne Muscular Dystrophy. Schneider SM; Sridhar V; Bettis AK; Heath-Barnett H; Balog-Alvarez CJ; Guo LJ; Johnson R; Jaques S; Vitha S; Glowcwski AC; Kornegay JN; Nghiem PP Mol Imaging Biol; 2018 Oct; 20(5):780-788. PubMed ID: 29508262 [TBL] [Abstract][Full Text] [Related]
44. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20. Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823 [TBL] [Abstract][Full Text] [Related]
45. Force-controlled ultrasound to measure passive mechanical properties of muscle in Duchenne muscular dystrophy. Pigula AJ; Wu JS; Gilbertson MW; Darras BT; Rutkove SB; Anthony BW Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():2865-2868. PubMed ID: 28324973 [TBL] [Abstract][Full Text] [Related]
46. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Wokke BH; van den Bergen JC; Versluis MJ; Niks EH; Milles J; Webb AG; van Zwet EW; Aartsma-Rus A; Verschuuren JJ; Kan HE Neuromuscul Disord; 2014 May; 24(5):409-16. PubMed ID: 24613733 [TBL] [Abstract][Full Text] [Related]
47. Muscle-MRI and Functional Levels for the Evaluation of Upper Limbs in Duchenne Muscular Dystrophy: A Critical Review of the Literature. Cristiano L; Brogna C; Tasca G; Verdolotti T; Pane M; Mercuri E Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334617 [TBL] [Abstract][Full Text] [Related]
48. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. Wren TA; Bluml S; Tseng-Ong L; Gilsanz V AJR Am J Roentgenol; 2008 Jan; 190(1):W8-12. PubMed ID: 18094282 [TBL] [Abstract][Full Text] [Related]
49. Can a newer MR contrast agent be used to monitor disease progression in muscular dystrophy? Unger EC Radiology; 2009 Jan; 250(1):1-3. PubMed ID: 19092081 [No Abstract] [Full Text] [Related]
50. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis. Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Schroeder J; Naduvilekoot Devasia A; Zuesli S; Bernert G; Laugel V; Bloetzer C; Steinlin M; Capone A; Gloor M; Tobler P; Haas T; Bieri O; Zumbrunn T; Fischer D; Bonati U Neuromuscul Disord; 2018 Jan; 28(1):16-23. PubMed ID: 29174526 [TBL] [Abstract][Full Text] [Related]
51. The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials. Chrzanowski SM; Darras BT; Rutkove SB Neurotherapeutics; 2020 Jan; 17(1):142-152. PubMed ID: 31879850 [TBL] [Abstract][Full Text] [Related]
52. Quantitative Skeletal Muscle MRI: Part 1, Derived T2 Fat Map in Differentiation Between Boys With Duchenne Muscular Dystrophy and Healthy Boys. Johnston JH; Kim HK; Merrow AC; Laor T; Serai S; Horn PS; Kim DH; Wong BL AJR Am J Roentgenol; 2015 Aug; 205(2):W207-15. PubMed ID: 26204309 [TBL] [Abstract][Full Text] [Related]
53. Muscle ultrasound quantifies disease progression over time in infants and young boys with duchenne muscular dystrophy. Zaidman CM; Malkus EC; Connolly AM Muscle Nerve; 2015 Sep; 52(3):334-8. PubMed ID: 25704979 [TBL] [Abstract][Full Text] [Related]
54. Longitudinal 2-point dixon muscle magnetic resonance imaging in becker muscular dystrophy. Bonati U; Schmid M; Hafner P; Haas T; Bieri O; Gloor M; Fischmann A; Fischer D Muscle Nerve; 2015 Jun; 51(6):918-21. PubMed ID: 25736228 [TBL] [Abstract][Full Text] [Related]
55. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy. Bonati U; Hafner P; Schädelin S; Schmid M; Naduvilekoot Devasia A; Schroeder J; Zuesli S; Pohlman U; Neuhaus C; Klein A; Sinnreich M; Haas T; Gloor M; Bieri O; Fischmann A; Fischer D Neuromuscul Disord; 2015 Sep; 25(9):679-85. PubMed ID: 26096788 [TBL] [Abstract][Full Text] [Related]
56. Abnormal lipid metabolism in skeletal muscle tissue of patients with muscular dystrophy: In vitro, high-resolution NMR spectroscopy based observation in early phase of the disease. Srivastava NK; Yadav R; Mukherjee S; Pal L; Sinha N Magn Reson Imaging; 2017 May; 38():163-173. PubMed ID: 28069416 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of muscular changes by ultrasound Nakagami imaging in Duchenne muscular dystrophy. Weng WC; Tsui PH; Lin CW; Lu CH; Lin CY; Shieh JY; Lu FL; Ee TW; Wu KW; Lee WT Sci Rep; 2017 Jun; 7(1):4429. PubMed ID: 28667314 [TBL] [Abstract][Full Text] [Related]
58. Eliminating Nox2 reactive oxygen species production protects dystrophic skeletal muscle from pathological calcium influx assessed in vivo by manganese-enhanced magnetic resonance imaging. Loehr JA; Stinnett GR; Hernández-Rivera M; Roten WT; Wilson LJ; Pautler RG; Rodney GG J Physiol; 2016 Nov; 594(21):6395-6405. PubMed ID: 27555555 [TBL] [Abstract][Full Text] [Related]
59. Muscle MRI: A biomarker of disease severity in Duchenne muscular dystrophy? A systematic review. Ropars J; Gravot F; Ben Salem D; Rousseau F; Brochard S; Pons C Neurology; 2020 Jan; 94(3):117-133. PubMed ID: 31892637 [TBL] [Abstract][Full Text] [Related]